Talphera logo

TalpheraNASDAQ: TLPH

Profile

Sector:

Healthcare

Country:

United States

IPO:

11 February 2011

Next earnings report:

06 March 2025

Last dividends:

N/A

Next dividends:

N/A
$12.43 M
-87%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:25:08 GMT
$0.73+$0.00(+0.54%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

TLPH Latest News

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Talphera, Inc. (NASDAQ:TLPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Conference Call Participants James Molloy - Alliance Global Partners Thomas Yip - H.C. Wainwright Operator Welcome to the Talphera Third Quarter 2024 Financial Results Conference Call.

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
prnewswire.com08 October 2024 Sentiment: POSITIVE

SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors.

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
prnewswire.com19 August 2024 Sentiment: POSITIVE

The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
prnewswire.com05 August 2024 Sentiment: POSITIVE

SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m.

Talphera to Participate at A.G.P. Virtual Healthcare Conference
prnewswire.com16 May 2024 Sentiment: POSITIVE

SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company specializing in developing and selling innovative therapies for medically supervised use, announced today that its management will take part in a fireside chat at the A.G.P.

What type of business is Talphera?

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

What sector is Talphera in?

Talphera is in the Healthcare sector

What industry is Talphera in?

Talphera is in the Drug Manufacturers - Specialty & Generic industry

What country is Talphera from?

Talphera is headquartered in United States

When did Talphera go public?

Talphera initial public offering (IPO) was on 11 February 2011

What is Talphera website?

https://talphera.com

Is Talphera in the S&P 500?

No, Talphera is not included in the S&P 500 index

Is Talphera in the NASDAQ 100?

No, Talphera is not included in the NASDAQ 100 index

Is Talphera in the Dow Jones?

No, Talphera is not included in the Dow Jones index

When was Talphera the previous earnings report?

No data

When does Talphera earnings report?

The next expected earnings date for Talphera is 06 March 2025